Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002034671-25-000003
Filing Date
2025-10-15
Accepted
2025-10-15 18:00:17
Documents
1
Period of Report
2025-10-13

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1760565614.html 4  
1 FORM 4 wk-form4_1760565614.xml 4 12828
  Complete submission text file 0002034671-25-000003.txt   14278
Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Issuer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address BICARA THERAPEUTICS INC. 116 HUNTINGTON AVENUE, SUITE 703 BOSTON MA 02116
Business Address
Mazumdar Claire (Reporting) CIK: 0002034671 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-42271 | Film No.: 251395933